Cover Image
Market Research Report

US Generic Drug Market Outlook 2018

Published by RNCOS E-Services Pvt. Ltd. Product code 324705
Published Content info 110 Pages
Immediate Delivery Available
Price
Back to Top
US Generic Drug Market Outlook 2018
Published: February 1, 2015 Content info: 110 Pages
Description

The US is the largest pharmaceutical market in the world. Driven by the factors such as large healthcare spending, high per-capita income, and strong research & development investments, the pharmaceutical market in the US has witnessed an upward surge over the past few years. Additionally, the share of Generics has increased steadily in the pharmaceutical market, in terms of both revenue and prescriptions.

The US generic drugs market accounts for a share of around 45% in the global Generics market. This share has been growing at a fast pace on the back of factors, such as demand for cost-effective medications, rising healthcare expenditure, increasing ageing population, patent expiration of blockbuster drugs, and enhanced government support. Besides, factors such as surging drug prices, lack of FDA support, long product approval process, and legal controversies related to drug approvals are holding back growth in the Generics industry.

According to RNCOS "US Generic Drug Market Outlook 2018", the US Generics market, which was US$ 43.5 Billion in 2013, is anticipated to grow at a CAGR of around 11% during 2013-2018. Currently, the market is witnessing significant developments in terms of new product categories that are attracting huge investments from both public and private players. The Generics market in the US will showcase a healthy growth potential in various therapy segments, such as oncology, respiratory, thyroid, ulcers as well as cholesterol disorders in the coming years. Growth in the aforementioned segments will be the result of patent expirations of a number of the major drugs in the next few years. The support from the US government in the form of approvals and incentives, will also act as a catalyst for future growth in the generic domain.

The report covers all the important aspects of the US Generics market and provides an in-depth analysis on the current status of the market, emerging trends, competitive landscape and future outlook, among other pointers. It also provides valuable information to pharmaceutical and generic drug companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.

Table of Contents

Table of Contents

1. Analyst View

2. Research Methodology

3. Market Drivers

  • 3.1 Inclining Healthcare Expenditure
  • 3.2 Rising Disposable Incomes
  • 3.3 Increasing Ageing Population
  • 3.4 Patent Expiry of Blockbuster Drugs
  • 3.5 Mergers & Acquisitions

4. Market Challenges

  • 4.1 Surging Generic Drug Prices
  • 4.2 Long Product Approval Process
  • 4.3 Legal Controversies

5. Overview of Generics Sector

  • 5.1 US Pharmaceutical Market
  • 5.2 Share of Branded vs. Generics
  • 5.3 Generics Drugs Market

6. Market Potential for Generic Drugs in Key Therapies Segments

  • 6.1 Oncology
  • 6.2 Obesity & Cholesterol
  • 6.3 Mental Health (Antipsychotics & Anti-Depressants)
  • 6.4 Hypertension (Angiotensin II Receptor)
  • 6.5 Diabetes
  • 6.6 Anti-Ulcerants (Proton Pump Inhibitors)
  • 6.7 Thyroid
  • 6.8 Respiratory

7. Market Trends & Developments

  • 7.1 New Product Launch
  • 7.2 Launch of Biosimilars (BioGenerics)
  • 7.3 Progress in User Fees for Generic Manufacturers (GDUFA)
  • 7.4 Revision of Pay-for-delay Agreement Policies

8. Regulatory Environment

  • 8.1 Drug Efficacy Study Implementation (DESI) Program
  • 8.2 Hatch-Waxman Act
  • 8.3 Patent Infringement Litigations
  • 8.4 Para IV & the 180-day Marketing Exclusivity
  • 8.5 FDA Requirements
  • 8.6 Generic Initiative for Value & Efficiency (GIVE)
  • 8.7 Healthcare Bill 2013
  • 8.8 Ban on "Pay for delay" Settlements
  • 8.9 Patient Protection and Affordable Care Act

9. Competitive Landscape

  • 9.1 Market Share of Leading Players
  • 9.2 Market Share of Leading Generic Drugs
  • 9.3 Profiles
    • 9.3.1 Teva Pharmaceuticals USA
    • 9.3.2 Actavis Plc
    • 9.3.3 Mylan Inc.
    • 9.3.4 Pfizer Inc.
    • 9.3.5 Sandoz Inc. (Novartis)
    • 9.3.6 Endo International Plc.
    • 9.3.7 Lupin Limited
    • 9.3.8 Dr. Reddy's Laboratories Ltd.
    • 9.3.9 Zydus Pharmaceuticals Inc.
    • 9.3.10 Amneal Pharmaceuticals

List of Figures:

  • Figure 3-1: Personal Disposable Income (Billion US$), 2008-2013
  • Figure 3-2: Total Health Expenditure (Billion US$), 2008-2013
  • Figure 3-3: Share of Public & Private Health Expenditure (2008-2013)
  • Figure 3-4: Population above 65 Years (Million), 2008-2013
  • Figure 5-1: US Pharmaceutical Market (Billion US$), 2013-2018
  • Figure 5-2: US Pharmaceutical Supply Chain
  • Figure 5-3: Share of Branded and Generics Drugs by Revenue (2013)
  • Figure 5-4: Market Share by Total Prescriptions (2011-2013)
  • Figure 5-5: Generic Drugs Market (Billion US$), 2013-2018
  • Figure 6-1: Estimated Cancer Deaths (2012 & 2013)
  • Figure 6-2: Adult Obesity Rate (%), 2013 & 2030
  • Figure 6-3: Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
  • Figure 8-1: Generic Drugs Approval Process
  • Figure 9-1: Share of Key Players in Generics Market (2013)
  • Figure 9-2: Teva Pharmaceuticals - Generics Revenue Share by Geographic Regions (2014)
  • Figure 9-3: Actavis Plc - Revenue Share by Geographic Regions (2013)
  • Figure 9-4: Mylan Inc - Revenue Share by Geographic Regions (2013)
  • Figure 9-5: Mylan Inc - Generics Revenue Share by Geographic Region (2014)
  • Figure 9-6: Pfizer - Revenue Share by Business Segments (2013)
  • Figure 9-7: Pfizer - Revenue Share by Geographical Regions (2013)
  • Figure 9-8: Sandoz - Revenue Share by Business Segments (2014)
  • Figure 9-9: Novartis - Revenue Share by Geographic Regions (2014)
  • Figure 9-10: Endo International Plc - Revenue Share by Business Segments (2013)
  • Figure 9-11: Lupin Ltd - Revenue Share by Business Segments (2013)
  • Figure 9-12: Lupin Ltd - Generics Share in the US by Value (2012 & 2013)
  • Figure 9-13: Lupin Ltd - Revenue Share by Geographic Regions (2013)
  • Figure 9-14: Dr. Reddy's Laboratory - Revenue Share by Business Segments (2013)
  • Figure 9-15: Dr. Reddy's Laboratory - Revenue Share by Geographical Regions (2013)
  • Figure 9-16: Amneal Pharmaceuticals - Revenue (Million US$), 2007 & 2014

List of Tables:

  • Table 3-1: Total Health Expenditure (% of GDP), 2008-2013
  • Table 3-2: Blockbuster Drugs Going Off Patent (2014-2016)
  • Table 3-3: Premium Deals in the US Generics Industry (2013- 2015)
  • Table 6-1: Patent Expiration of Key Oncology Drugs
  • Table 6-2: Patent Expiration of Key Antipsychotic Drugs
  • Table 6-3: Patent Expiration of Key Antidepressant Drugs
  • Table 6-4: Prevalence of High Blood Pressure by Age & Gender (2013)
  • Table 6-5: Patent Expiration of Key Human Insulin Drugs
  • Table 6-6: Top 10 Proton Pump Inhibitors by Sales (Million US$), 2013
  • Table 6-7: Patent Expiration of Key Proton Pump Inhibitors
  • Table 6-8: Patent Expiry of Key Thyroid Drugs
  • Table 6-9: Patent Expiry of Key Respiratory Drugs
  • Table 7-1: Generic Drugs Launched in the US Market (2013 & 2014)
  • Table 7-2: List of Biosimilars under Development in the US
  • Table 9-1: Top Generic Drugs by Sales (Million US$), 2013
  • Table 9-2: Top Generic Drugs by Prescription (2013)
  • Table 9-3: Teva Pharmaceuticals - Revenue by Business Segments (Million US$), 2013 & 2014
  • Table 9-4: Teva Pharmaceuticals - Generics Revenue by Geographic Regions (Million US$), 2013 & 2014
  • Table 9-5: Actavis Plc - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 9-6: Mylan Inc - Revenue by Business Segments (Million US$), 2013 & 2014
  • Table 9-7: Pfizer - Revenue by Business Segments (Million US$), 2011-2013
  • Table 9-8: Endo International Inc - Revenue by Companies (Million US$), 2011-2013
  • Table 9-9: Lupin Ltd - Revenue by Business Segments (Million US$), 2011-2013
  • Table 9-10: Dr. Reddy's Laboratory - Revenue by Business Segments (Million US$), 2011-2013
Back to Top